Side-by-side comparison of AI visibility scores, market position, and capabilities
Saint Paul MN water treatment and hygiene (NYSE: ECL) $15.7B FY2024 revenue (+5% organic); 25K+ field associates, food safety, data center cooling water treatment opportunity competing with Nalco/Dow and Diversey.
Ecolab Inc. is a Saint Paul, Minnesota-based water treatment, hygiene, and infection prevention company — publicly traded on the New York Stock Exchange (NYSE: ECL) as an S&P 500 Materials component — providing products, equipment, and services for cleaning, sanitizing, water treatment, and infection prevention to food processing plants, restaurants, hotels, hospitals, commercial laundries, power plants, and industrial facilities through approximately 47,000 employees ("associates") in 170 countries. In fiscal year 2024, Ecolab reported revenues of $15.7 billion (+5% organic growth) with record operating income and adjusted diluted EPS growth as the company benefited from pricing actions implemented in 2022-2023 to recover raw material cost inflation, while raw material costs normalized — creating margin expansion on pricing that persisted after input costs declined. CEO Christophe Beck has positioned Ecolab's growth strategy around three secular demand themes: water scarcity (food processing and industrial companies reducing water consumption per unit of output through Ecolab's water recycling and closed-loop treatment chemistry), food safety (food processors and restaurants requiring validated sanitization programs that meet FDA FSMA regulatory requirements for pathogen control), and infection prevention (healthcare facilities requiring hospital-grade disinfectants, surgical scrubs, and environmental hygiene programs that comply with CDC and Joint Commission standards). Ecolab's three divisions — Institutional & Specialty (restaurants, hotels, laundry — $7B+ revenue), Industrial (food processing, beverage, pharma, water treatment — $5B+ revenue), and Healthcare & Life Sciences ($1.5B+ revenue) — serve complementary end markets with differentiated chemistry and service programs.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.